Crohn's disease (moderate to severe) - vedolizumab: committee papers
Table of contents
01. NICE's response to comments on the Appraisal Consultation Document (ACD)
02. Consultee comments on the ACD - Takeda (Vedolizumab)
03. Consultee comments on the ACD - AbbVie
04. Consultee comments on the ACD - BSG
05. Consultee comments on the ACD - Crohn's & Colitis UK
06. Consultee comments on the ACD - Crohn's & Colitis UK
07. Consultee comments on the ACD - Merck Sharpe and Dohme
08. Consultee comments on the ACD - Royal College Nursing
09. Consultee comments on the ACD - United Kingdom Clinical Pharmacy Association
10. Public comments on the ACD received via the NICE website
11. Evidence Review Group - Final report critique
|
Crohn's disease (moderate to severe) - vedolizumab: committee papers
10 July 2015 (5.44 Mb 3 sec) |
This page was last updated: 08 July 2015